Admission of the Company’s Ordinary Shares

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to confirm that following the Company’s financing as announced on 18 October 2022, Admission of the 7,368,427 new Placing Shares and the 15,000 new Management Subscription Shares took place at 8.00 a.m. today.

Capitalised terms used but not otherwise defined in the text of this announcement shall have the meaning given to them in the Company’s announcements on the 18 October 2022.

Following Admission, the Company’s enlarged issued ordinary share capital will be 263,732,659. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure Guidance and Transparency Rules.